Erytech Pharma SA ADR
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $31.31 million
- Book Value:
- Revenue TTM:
- $6.65 million
- Operating Margin TTM:
- Gross Profit TTM:
- $4.18 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Erytech Pharma SA ADR had its IPO on 2016-07-05 under the ticker symbol ERYP.
The company operates in the Healthcare sector and Biotechnology industry. Erytech Pharma SA ADR has a staff strength of 49 employees.
Shares of Erytech Pharma SA ADR opened at $0.91 at the start of the last trading session i.e. 2023-06-02.
The stocks traded within a range of $0.91 - $0.93, and closed at $0.92.
This is a +5.03% increase from the previous day's closing price.
A total volume of 1,855 shares were traded at the close of the day’s session.
In the last one week, shares of Erytech Pharma SA ADR have slipped by -8.2%.
Erytech Pharma SA ADR's Key Ratios
Erytech Pharma SA ADR has a market cap of $31.31 million, indicating a price to book ratio of 0.6542 and a price to sales ratio of 7.5782.
In the last 12-months Erytech Pharma SA ADR’s revenue was $6.65 million with a gross profit of $4.18 million and an EBITDA of $-24972000. The EBITDA ratio measures Erytech Pharma SA ADR's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Erytech Pharma SA ADR’s operating margin was -408.41% while its return on assets stood at -30.14% with a return of equity of -0.98%.
In Q4, Erytech Pharma SA ADR’s quarterly earnings growth was a positive 0% while revenue growth was a positive 571.5%.
Erytech Pharma SA ADR’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.01 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Erytech Pharma SA ADR’s profitability.
Erytech Pharma SA ADR stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 2.6278. Its price to sales ratio in the trailing 12-months stood at 7.5782.
Erytech Pharma SA ADR stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $45.81 million
- Total Liabilities
- $11.68 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Erytech Pharma SA ADR ended 2023 with $45.81 million in total assets and $0 in total liabilities. Its intangible assets were valued at $45.81 million while shareholder equity stood at $23.49 million.
Erytech Pharma SA ADR ended 2023 with $0 in deferred long-term liabilities, $11.68 million in other current liabilities, 3102000.00 in common stock, $-228000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $38.79 million and cash and short-term investments were $38.83 million. The company’s total short-term debt was $3,340,000 while long-term debt stood at $7.55 million.
Erytech Pharma SA ADR’s total current assets stands at $42.63 million while long-term investments were $0 and short-term investments were $43000.00. Its net receivables were $2.53 million compared to accounts payable of $1.56 million and inventory worth $0.00.
In 2023, Erytech Pharma SA ADR's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Erytech Pharma SA ADR paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Erytech Pharma SA ADR stock is currently trading at $0.92 per share. It touched a 52-week high of $1.472 and a 52-week low of $1.472. Analysts tracking the stock have a 12-month average target price of $2.96.
Its 50-day moving average was $0.91 and 200-day moving average was $0.76 The short ratio stood at 0.23 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 765.2% are held by institutions.
Frequently Asked Questions About Erytech Pharma SA ADR
Similar Industry Stocks (Biotechnology)
ERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-“-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.